Literature DB >> 22151832

Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets.

H Seif El Nasr1, O G Shaker, M M T Fawzi, G El-Hanafi.   

Abstract

BACKGROUND: In healthy skin, there is a molecular microenvironment that favours the survival of melanocytes and regulates their function. Keratinocytes synthesize and secrete several cytokines that have stimulatory and inhibitory effects on melanocytes. AIM OF THE WORK: This work was conducted to evaluate the expression of basic fibroblast growth factor (bFGF) and tumour necrosis factor alpha (TNF-α) mRNA levels in lesional skin of vitiligo, hypopigmented mycosis fungoides and hypopigmented tinea versicolor. PATIENTS AND METHODS: Forty eight patients (25 vitiligo, 14 hypopigmented mycosis fungoides, 9 hypopigmented tinea versicolor) and 10 healthy controls were included. A 4 mm punch skin biopsy was taken from lesional skin of patients, and the normal skin of controls for quantitative PCR examination of TNF-α and bFGF mRNA.
RESULTS: The level of TNF-α mRNA in lesional skin of the three studied disorders was significantly higher than in the control group, while the level of bFGF mRNA was significantly lower in lesional skin of the three diseases than the control skin. A significant inverse correlation was demonstrated between the mRNA levels of the two studied cytokines in vitiligo and hypopigmented MF lesions.
CONCLUSION: The study's findings demonstrate that the studied hypopigmented (vitiligo, hypopigmented MF, hypopigmented TV) disorders show similar changes in their cutaneous microenvironment with increased TNF-α and decreased bFGF mRNA expression. This cytokine microenvironment change may be implicated in the pigment loss and hence these cytokines may have future therapeutic implications.
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22151832     DOI: 10.1111/j.1468-3083.2011.04368.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  8 in total

1.  Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Ann Transl Med       Date:  2015-12

2.  Follicular Transplantation, Microneedling, and Adjuvant Narrow-band Ultraviolet-B Irradiation as Cost-Effective Regimens for Palmar-Plantar Vitiligo: A Pilot Study.

Authors:  Amir Feily; Abdollah Firoozifard; Toktam Sokhandani; Perla Elosegui-Rodriguez; Evian Perez-Rivera; Christopher S Lange; Masoomeh Hosseinpoor; Marigdalia K Ramirez-Fort
Journal:  Cureus       Date:  2020-04-28

3.  Vitiligo and alopecia areata: apples and oranges?

Authors:  John E Harris
Journal:  Exp Dermatol       Date:  2013-12       Impact factor: 3.960

Review 4.  Participation of keratinocyte- and fibroblast-derived factors in melanocyte homeostasis, the response to UV, and pigmentary disorders.

Authors:  Parth R Upadhyay; Tina Ho; Zalfa A Abdel-Malek
Journal:  Pigment Cell Melanoma Res       Date:  2021-05-24       Impact factor: 4.693

5.  Evaluation of cardiovascular disease risk factors in patients with mycosis fungoides.

Authors:  Fatma Pelin Cengiz; Nazan Emiroglu
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

6.  Interferon-γ induces senescence in normal human melanocytes.

Authors:  Suiquan Wang; Miaoni Zhou; Fuquan Lin; Dongyin Liu; Weisong Hong; Liangjun Lu; Yiping Zhu; Aie Xu
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240

7.  The Difference in Expression of Autophagy-Related Proteins in Lesional and Perilesional Skin in Adult Patients with Active and Stable Generalized Vitiligo-A Cross-Sectional Pilot Study.

Authors:  Haiyan Yu; Xiaoxia Lin; Yaoyao Huang; Hao Cheng; Oliver Seifert
Journal:  Indian J Dermatol       Date:  2021 Jul-Aug       Impact factor: 1.494

Review 8.  Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology.

Authors:  Fabricio Cecanho Furlan; José Antonio Sanches
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.